FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022052618> ?p ?o ?g. }

• W2022052618 endingPage "284" @default.
• W2022052618 startingPage "281" @default.
• W2022052618 abstract "To describe the treatment response with melatonin for rapid eye movement (REM) sleep behavior disorder (RBD) associated with other neurologic disorders.Clonazepam has been considered the treatment of choice for RBD. However, an alternative treatment is desirable for those with RBD refractory to clonazepam, for those who experience intolerable side-effects with clonazepam, and for those in whom clonazepam precipitates or aggravates obstructive sleep apnea (OSA). To date, there is minimal published data and limited follow-up regarding the use of melatonin for patients with RBD associated with other neurologic syndromes and disorders.The response to melatonin treatment for RBD was reviewed on consecutive patients the investigators treated with this agent at Mayo Clinic Rochester from January 2000 to June 2001. The coexisting neurologic disorders, reasons for using melatonin, effective doses, side-effects, and duration of follow-up were also reviewed on all patients.Fourteen patients were commenced on melatonin over the specified time period (13 male, median RBD onset age 56 years, range 20-77 years). The coexisting neurologic findings/disorders were dementia with Lewy bodies (n=7), mild cognitive impairment with mild parkinsonism (n=2), multiple system atrophy (n=2), narcolepsy (n=2), and Parkinson's disease (n=1). The reasons for using melatonin in these cases were incomplete response of RBD to clonazepam in six patients, existing cognitive impairment in five, intolerable side-effects with clonazepam in two, and presence of severe obstructive sleep apnea and narcolepsy in one. With seven patients continuing to use clonazepam at 0.5-1.0 mg/night, RBD was controlled in six patients, significantly improved in four, and initially improved but subsequently returned in two; no improvement occurred in one patient and increased RBD frequency/severity occurred in one patient. The effective melatonin doses were 3 mg in two cases, 6 mg in seven cases, 9 mg in one case, and 12 mg in two cases. Five patients reported side-effects, which included morning headaches (2), morning sleepiness (2), and delusions/hallucinations (1); these symptoms resolved with decreased dosage. The mean duration of follow-up was 14 months (range 9-25 months), with eight patients experiencing continued benefit with melatonin beyond 12 months of therapy.In this series, persistent benefit with melatonin beyond 1 year of therapy occurred in most but not all patients. Melatonin can be considered as a possible sole or add-on therapy in select patients with RBD. Prospective, long-term, controlled trials with melatonin are warranted in a larger number of patients with RBD associated with a variety of neurologic symptoms and disorders." @default.
• W2022052618 created "2016-06-24" @default.
• W2022052618 creator A5066352714 @default.
• W2022052618 date "2003-07-01" @default.
• W2022052618 modified "2023-10-18" @default.
• W2022052618 title "Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients" @default.
• W2022052618 cites W1998770249 @default.
• W2022052618 cites W2002894477 @default.
• W2022052618 cites W2010139043 @default.
• W2022052618 cites W2049357869 @default.
• W2022052618 cites W2057134922 @default.
• W2022052618 cites W2085992732 @default.
• W2022052618 cites W2086120642 @default.
• W2022052618 cites W2108410348 @default.
• W2022052618 cites W2113235404 @default.
• W2022052618 cites W2123056519 @default.
• W2022052618 cites W2129269087 @default.
• W2022052618 cites W2130367817 @default.
• W2022052618 cites W2130741672 @default.
• W2022052618 cites W2143092088 @default.
• W2022052618 cites W2159011576 @default.
• W2022052618 cites W2159122349 @default.
• W2022052618 cites W2321031001 @default.
• W2022052618 cites W2332602680 @default.
• W2022052618 cites W2334875551 @default.
• W2022052618 doi "https://doi.org/10.1016/s1389-9457(03)00072-8" @default.
• W2022052618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14592300" @default.
• W2022052618 hasPublicationYear "2003" @default.
• W2022052618 type Work @default.
• W2022052618 sameAs 2022052618 @default.
• W2022052618 citedByCount "322" @default.
• W2022052618 countsByYear W20220526182012 @default.
• W2022052618 countsByYear W20220526182013 @default.
• W2022052618 countsByYear W20220526182014 @default.
• W2022052618 countsByYear W20220526182015 @default.
• W2022052618 countsByYear W20220526182016 @default.
• W2022052618 countsByYear W20220526182017 @default.
• W2022052618 countsByYear W20220526182018 @default.
• W2022052618 countsByYear W20220526182019 @default.
• W2022052618 countsByYear W20220526182020 @default.
• W2022052618 countsByYear W20220526182021 @default.
• W2022052618 countsByYear W20220526182022 @default.
• W2022052618 countsByYear W20220526182023 @default.
• W2022052618 crossrefType "journal-article" @default.
• W2022052618 hasAuthorship W2022052618A5066352714 @default.
• W2022052618 hasConcept C118552586 @default.
• W2022052618 hasConcept C126322002 @default.
• W2022052618 hasConcept C1513209611 @default.
• W2022052618 hasConcept C15744967 @default.
• W2022052618 hasConcept C16568411 @default.
• W2022052618 hasConcept C187212893 @default.
• W2022052618 hasConcept C2776006263 @default.
• W2022052618 hasConcept C2776132596 @default.
• W2022052618 hasConcept C2776525014 @default.
• W2022052618 hasConcept C2778182776 @default.
• W2022052618 hasConcept C2778205975 @default.
• W2022052618 hasConcept C2778548049 @default.
• W2022052618 hasConcept C2779134260 @default.
• W2022052618 hasConcept C2779426884 @default.
• W2022052618 hasConcept C2779483572 @default.
• W2022052618 hasConcept C2779494582 @default.
• W2022052618 hasConcept C2781210498 @default.
• W2022052618 hasConcept C2781326671 @default.
• W2022052618 hasConcept C42219234 @default.
• W2022052618 hasConcept C71924100 @default.
• W2022052618 hasConceptScore W2022052618C118552586 @default.
• W2022052618 hasConceptScore W2022052618C126322002 @default.
• W2022052618 hasConceptScore W2022052618C1513209611 @default.
• W2022052618 hasConceptScore W2022052618C15744967 @default.
• W2022052618 hasConceptScore W2022052618C16568411 @default.
• W2022052618 hasConceptScore W2022052618C187212893 @default.
• W2022052618 hasConceptScore W2022052618C2776006263 @default.
• W2022052618 hasConceptScore W2022052618C2776132596 @default.
• W2022052618 hasConceptScore W2022052618C2776525014 @default.
• W2022052618 hasConceptScore W2022052618C2778182776 @default.
• W2022052618 hasConceptScore W2022052618C2778205975 @default.
• W2022052618 hasConceptScore W2022052618C2778548049 @default.
• W2022052618 hasConceptScore W2022052618C2779134260 @default.
• W2022052618 hasConceptScore W2022052618C2779426884 @default.
• W2022052618 hasConceptScore W2022052618C2779483572 @default.
• W2022052618 hasConceptScore W2022052618C2779494582 @default.
• W2022052618 hasConceptScore W2022052618C2781210498 @default.
• W2022052618 hasConceptScore W2022052618C2781326671 @default.
• W2022052618 hasConceptScore W2022052618C42219234 @default.
• W2022052618 hasConceptScore W2022052618C71924100 @default.
• W2022052618 hasIssue "4" @default.
• W2022052618 hasLocation W20220526181 @default.
• W2022052618 hasLocation W20220526182 @default.
• W2022052618 hasOpenAccess W2022052618 @default.
• W2022052618 hasPrimaryLocation W20220526181 @default.
• W2022052618 hasRelatedWork W1716330440 @default.
• W2022052618 hasRelatedWork W1999506197 @default.
• W2022052618 hasRelatedWork W20391917 @default.
• W2022052618 hasRelatedWork W2171507350 @default.
• W2022052618 hasRelatedWork W2907107566 @default.
• W2022052618 hasRelatedWork W2938740480 @default.
• W2022052618 hasRelatedWork W3026773820 @default.
• W2022052618 hasRelatedWork W3154418832 @default.

• next